US 12,245,805 B2
Compositions, systems, kits, and methods for neural ablation
Guillermo Alas, Alpharetta, GA (US); Michael G. Smith, Alpharetta, GA (US); Sherry E. Adesina, Tucker, GA (US); and Alencia V. Washington, Roswell, GA (US)
Assigned to Avent, Inc., Alpharetta, GA (US)
Filed by Avent, Inc., Alpharetta, GA (US)
Filed on Sep. 3, 2020, as Appl. No. 17/011,927.
Application 17/011,927 is a continuation of application No. 16/653,298, filed on Oct. 15, 2019, granted, now 10,799,289.
Claims priority of provisional application 62/745,826, filed on Oct. 15, 2018.
Claims priority of provisional application 62/745,831, filed on Oct. 15, 2018.
Claims priority of provisional application 62/745,835, filed on Oct. 15, 2018.
Claims priority of provisional application 62/745,973, filed on Oct. 15, 2018.
Prior Publication US 2021/0106383 A1, Apr. 15, 2021
Int. Cl. A61B 18/14 (2006.01); A61L 24/00 (2006.01); A61L 24/04 (2006.01); A61M 5/00 (2006.01); A61M 25/00 (2006.01); A61B 17/00 (2006.01); A61B 18/00 (2006.01); A61B 18/02 (2006.01)
CPC A61B 18/1492 (2013.01) [A61L 24/001 (2013.01); A61L 24/046 (2013.01); A61M 5/007 (2013.01); A61M 25/0082 (2013.01); A61B 2017/00292 (2013.01); A61B 2017/00362 (2013.01); A61B 17/00491 (2013.01); A61B 2018/00005 (2013.01); A61B 2018/00434 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/0212 (2013.01); A61L 2400/06 (2013.01); A61M 2205/054 (2013.01); A61M 2205/3606 (2013.01)] 19 Claims
OG exemplary drawing
 
1. A method for ameliorating pain in a subject in need thereof, the method comprising:
inserting an introducer cannula into the subject and positioning a distal end of the introducer cannula proximate a treatment site comprising a nerve that transmits a pain impulse;
injecting a liquid composition comprising a heat-activated biocompatible polymer through the introducer cannula and into the treatment site,
advancing an ablation probe through the introducer to a region proximate to the treatment site;
ablating the nerve with the ablation probe, thereby forming a lesion on the nerve; retracting the ablation probe;
wherein the liquid composition exhibits a viscosity of less than 1000 cP at 4° C.;
wherein upon heating to a temperature of from 40° C. to 70° C., the heat-activated biocompatible polymer forms a polymeric matrix that exhibits a viscosity of at least 25,000 cP at 37° C.; and
wherein the heat generated by the ablation probe induces the heat-activated biocompatible polymer to form the polymeric matrix at the treatment site.